spacer
home > ebr > spring 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Proteins, proteins, proteins. They are a main feature in our spring edition of EBR – perhaps not surprisingly, considering the continued increase in adoption to clinical practice of high-value, high-performing protein therapeutics and the need for their manufacture at scale by the biopharmaceutical industry.

Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab would argue that, considering the market size and recent numbers of US and European approvals in these drug classes, the future for mid-size contract development and manufacturing organisations lies in complex proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and proteins for cancer and autoimmune conditions in particular (see full pdf). In their articles, Christian Loch from AVMBioMed (see full pdf) and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full pdf) agree that, at present, proteomics is the best means for capturing this vital information.

AVMBioMed highlight the need to consider the importance of post-translational modification in defining the human protein repertoire, and the Trinean team plus Kris Gavaert and Francis Impens flag the need for further improvements in quality to move proteomics towards a unified regulatory process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

DrugDev Continues Robust Growth in Europe, Attracts Veteran Pharmaceutical Industry Senior Executive George Masoura as Vice President of Business Development


More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

RDD Europe 2017

25-28 April 2017, Palais des Congres d’Antibes, Nice (Antibes), France

RDD Europe 2017, organized by RDD Online and Aptar Pharma will be held in Nice (Antibes), France, April 25-28, 2017.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement